Inducible Laryngeal Obstruction in Severe Asthma in Severe Asthma
1 other identifier
observational
116
1 country
1
Brief Summary
The first part will be a comparative cross-sectional study to identify the frequency of ILO and other comorbidites among participants with asthma compared to a group of reference subjects without asthma, matched for age- and gender and race. The second part will be a longitudinally observational study study following participants for one year after the cross-sectional study. The Maat-scores ILO-symptoms and asthma-outcomes longitudinally will be evaluated, .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 13, 2020
CompletedFirst Posted
Study publicly available on registry
October 20, 2020
CompletedStudy Start
First participant enrolled
November 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2024
CompletedNovember 21, 2025
May 1, 2025
3.9 years
October 13, 2020
November 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Prevalence of ILO in the participants
Continues during exercise(CLE)-test score at 2 or more at glottis or supraglottic level (Score range 0 minimum -3 maximum) 3 is full closure, 0 i open.
One year
Changes in continues during exercise (CLE-)-test score
The absolute change from baseline CLE-score (Score range 0 minimum -3 maximum). 3 is full closure in larynx, 0 is open.
One year
Secondary Outcomes (4)
The prevalence of OSA in asthma patients with ILO.
One year
Changes in asthma-controll score (ACT)
One year
Number of asthma-exercabations
One year
Changes in mini-Asthma quality of life (m-AQLQ)
One year
Study Arms (3)
Severe asthma
Gina-guidlines treatment-step 5
Mild-moderate asthma
Gina-guidlines treatment-step 1-4
Subjects without asthma
Matches control-group without asthma
Interventions
Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
Eligibility Criteria
The sample size of the cohort with severe asthma will be: All patients with severe asthma followed in our clinic for severe asthma estimated to be around 80 participants, of them, we hope to recruit at least 40 to perform the CLE-test, and we plan to recruit 40 participants with mild asthma and 40 age- and gender matched control subjects without asthma
You may qualify if:
- Patients with severe asthma (GINA 5)
- Patients with mild-moderate well-treated asthma (GINA step 1-4)
- Agroup of age- and gender matched control subjects without asthma also aged 18- 70.
- The patients must have had a stable disease the last one month before performing the CLE-test
You may not qualify if:
- No have underlying neurologic disease.
- No known cancer in the lung-head-neck
- No known vocal cord pathology.
- No history of life-threatening asthma required hospitalization.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Haukeland University Hospital
Bergen, 5021, Norway
Related Publications (1)
Rogde AJ, Lehmann S, Halvorsen T, Clemm HH, Roksund OD, Hufthammer KO, Kvidaland HK, Vollsaeter M, Andersen TM. Prevalence and impact of exercise-induced laryngeal obstruction in asthma: a study protocol for a cross-sectional and longitudinal study. BMJ Open. 2023 Jun 16;13(6):e071159. doi: 10.1136/bmjopen-2022-071159.
PMID: 37328176DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sverre Lehmann, PhD
Haukeland University Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 13, 2020
First Posted
October 20, 2020
Study Start
November 1, 2020
Primary Completion
October 1, 2024
Study Completion
October 1, 2024
Last Updated
November 21, 2025
Record last verified: 2025-05